TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01929915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural patient controlled analgesia
Description: Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous patient controlled analgesia
Description: Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
Study: NCT01584102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group fitness + education
Description: 15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group fitness classes only
Description: 15 weeks biweekly group fitness
Study: NCT02837198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study: NCT00731341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation for the treatment of uterine fibroids
Description: Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
Study: NCT03344094

Intervention type: DRUG
Intervention: ocrelizumab
Description: FDA-approved MS drugs
Study: NCT01693822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Study: NCT02837198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study: NCT03548025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-703 (Treatment group)
Description: Treatment with BTL-FR2000 Device
Study: NCT04182399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide Capsules
Description: anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
Study: NCT02837198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiroxostat
Study: NCT02465216

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 + GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 + GLA-SE
Study: NCT01441206

Intervention type: DRUG
Group type: OTHER
Intervention: rifampin
Description: Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD
Study: NCT02622321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIa
Description: Participants will continue to receive rFVIIa.
Study: NCT02549027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: Oral MK-6096 tablets (5 mg strength)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: Oral MK-6096 tablets (5 mg strength)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
Study: NCT02622321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC
Description: Participants will continue to receive aPCC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aPCC
Description: Participants will continue to receive aPCC.
Study: NCT02385591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Support
Description: Telephone-based physical activity advice and support delivered by SMS.
Study: NCT02622321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC
Description: Participants will continue to receive aPCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aPCC
Description: Participants will continue to receive aPCC.
Study: NCT00965718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte
Description: Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
Study: NCT01634360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
Study: NCT02892071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 22% TCA peel
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser
Description: One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qs-NdYag laser
Description: Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
Study: NCT02052674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vented urinary drainage system
Description: This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-vented urinary drainage system
Description: This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
Study: NCT03660267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine coffee
Description: drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decaffiene coffee
Description: drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: still water
Description: drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine
Study: NCT03740061

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle
Study: NCT05422833

Intervention type: OTHER
Intervention: Evaluation and analysis of clinical data
Description: Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.

Intervention type: OTHER
Intervention: Evaluation and analysis of clinical data
Description: Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
Study: NCT01462422

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
Study: NCT03740061

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic assessment of muscle
Description: Ultrasonographic assessment of quadriceps muscle
Study: NCT01950507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Entocort EC 3 mg given orally three times daily for at least 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400 mg orally once daily for CrCl greater than or equal to 50 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
Study: NCT00646776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: Capsule, Oral, 150 mg, once daily, 11 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin + Atazanavir + Ritonavir
Description: Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)
Study: NCT02949102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crave Crush
Description: Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
Study: NCT03919214

Intervention type: OTHER
Group type: OTHER
Intervention: Automated Messaging
Description: This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
Study: NCT05219214

Intervention type: OTHER
Intervention: Chinese medicine
Description: There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
Study: NCT04802278

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Any COVID-19 vaccine
Study: NCT00912639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel loaded Polymeric micelle
Description: Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
Study: NCT03523806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution-Focused Coaching in Pediatric Rehabilitation
Description: A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
Study: NCT03725098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows
Description: The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLOSEAL
Description: The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
Study: NCT04147130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MultiPAP Plus
Description: Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.
Study: NCT03485547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
Study: NCT01603004

Intervention type: OTHER
Intervention: MRI
Description: Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
Study: NCT03700671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training
Description: The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
Study: NCT03812094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enurad 400
Description: Alarm treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Bladder advice
Description: Pre-specified Basic bladder advice
Study: NCT02323113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.
Study: NCT02860013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Study: NCT00160485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: dosage required to obtain adequate glucose control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: variable dosage to obtain glucose control
Study: NCT03724760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized repeated feedback approach
Description: Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
Study: NCT02007694

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
Study: NCT04352647

Intervention type: BEHAVIORAL
Intervention: female athletes
Description: The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance